$SEELQ
SEELOS THERAPEUTICS, INC.

2024 Q1 Form 10-K Financial Statement

#000141057824000140 Filed on March 06, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $579.0K $653.0K $2.203M
YoY Change -28.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.109M $2.746M $12.59M
YoY Change -23.65% -0.22% 2.35%
% of Gross Profit
Research & Development $3.525M $5.918M $30.12M
YoY Change -37.81% -61.83% -48.62%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $6.634M $8.664M $42.70M
YoY Change -31.89% -52.54% -39.79%
Operating Profit -$6.055M -$40.50M
YoY Change -32.21% -42.89%
Interest Expense $23.00K -$7.000K $75.00K
YoY Change 228.57% -117.5% 435.71%
% of Operating Profit
Other Income/Expense, Net $3.391M $2.565M $2.617M
YoY Change -175.37% -682.95% -199.96%
Pretax Income -$2.664M -$5.453M -$37.88M
YoY Change -80.17% -70.77% -48.48%
Income Tax
% Of Pretax Income
Net Earnings -$2.664M -$5.453M -$37.88M
YoY Change -80.17% -70.77% -48.48%
Net Earnings / Revenue -460.1% -835.07% -1719.56%
Basic Earnings Per Share -$0.20 -$7.73
Diluted Earnings Per Share -$0.20 -$0.79 -$7.73
COMMON SHARES
Basic Shares Outstanding 13.68M 161.4M 4.900M
Diluted Shares Outstanding 13.01M 4.900M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $524.0K $2.996M $2.996M
YoY Change -96.27% -80.71% -80.71%
Cash & Equivalents $524.0K $2.996M
Short-Term Investments
Other Short-Term Assets $2.058M $1.644M $1.644M
YoY Change -76.43% -76.98% -76.98%
Inventory
Prepaid Expenses
Receivables $968.0K $763.0K $763.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.550M $5.403M $5.403M
YoY Change -84.95% -76.17% -76.17%
LONG-TERM ASSETS
Property, Plant & Equipment $62.00K $15.00K $15.00K
YoY Change 6.9% -79.17% -79.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $62.00K $15.00K $15.00K
YoY Change 6.9% -79.17% -79.17%
TOTAL ASSETS
Total Short-Term Assets $3.550M $5.403M $5.403M
Total Long-Term Assets $62.00K $15.00K $15.00K
Total Assets $3.612M $5.418M $5.418M
YoY Change -84.72% -76.18% -76.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.27M $16.40M $16.40M
YoY Change 156.05% 352.37% 352.37%
Accrued Expenses $4.524M $2.516M $2.531M
YoY Change -19.2% -65.45% -65.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $13.08M $14.21M $14.21M
YoY Change 12.52% 19.79% 19.79%
Total Short-Term Liabilities $36.72M $38.93M $38.93M
YoY Change -6.34% 54.73% 54.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0% -100.0% -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.72M $38.93M $38.93M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $36.72M $38.93M $38.93M
YoY Change -17.12% 16.7% 16.7%
SHAREHOLDERS EQUITY
Retained Earnings -$255.3M -$252.6M
YoY Change 11.88% 17.65%
Common Stock $222.2M $219.1M
YoY Change 7.07% 7.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$33.10M -$33.51M -$33.51M
YoY Change
Total Liabilities & Shareholders Equity $3.612M $5.418M $5.418M
YoY Change -84.72% -76.18% -76.18%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$2.664M -$5.453M -$37.88M
YoY Change -80.17% -70.77% -48.48%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$4.642M -$1.912M -$23.91M
YoY Change -55.14% -85.39% -61.18%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.195M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.170M 2.325M 11.38M
YoY Change -75.55% -223.15% -812.27%
NET CHANGE
Cash From Operating Activities -4.642M -1.912M -23.91M
Cash From Investing Activities
Cash From Financing Activities 2.170M 2.325M 11.38M
Net Change In Cash -2.472M 413.0K -12.54M
YoY Change 67.71% -102.76% -80.16%
FREE CASH FLOW
Cash From Operating Activities -$4.642M -$1.912M -$23.91M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#GrantMember
CY2023 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2023#GrantMember
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001017491
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
false
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3572417
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9794594
CY2023Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.03
CY2022Q4 seel Threshold Consecutive Trading Days Considered For Bid Price
ThresholdConsecutiveTradingDaysConsideredForBidPrice
P30D
CY2023Q4 seel Threshold Consecutive Trading Days Considered For Bid Price
ThresholdConsecutiveTradingDaysConsideredForBidPrice
P30D
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
000-22245
CY2023 dei Entity Registrant Name
EntityRegistrantName
SEELOS THERAPEUTICS, INC.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0449967
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
300 Park Avenue
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
2nd Floor
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
CY2023 dei City Area Code
CityAreaCode
646
CY2023 dei Local Phone Number
LocalPhoneNumber
293-2100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
CY2023 dei Trading Symbol
TradingSymbol
SEEL
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
13680576
CY2023Q2 dei Entity Public Float
EntityPublicFloat
144900000
CY2023 dei Auditor Name
AuditorName
KPMG LLP
CY2023 dei Auditor Location
AuditorLocation
Short Hills, NJ
CY2023 dei Auditor Firm
AuditorFirmId
185
CY2023Q4 us-gaap Cash
Cash
2996000
CY2022Q4 us-gaap Cash
Cash
15533000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
763000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1644000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7141000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
5403000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
22674000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
15000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
72000
CY2023Q4 us-gaap Assets
Assets
5418000
CY2022Q4 us-gaap Assets
Assets
22746000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16403000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3626000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2516000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7282000
CY2022Q4 seel Licenses Payable
LicensesPayable
2195000
CY2023Q4 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
14213000
CY2022Q4 us-gaap Convertible Subordinated Debt Current
ConvertibleSubordinatedDebtCurrent
11865000
CY2023Q4 seel Warrant Liabilities At Fair Value
WarrantLiabilitiesAtFairValue
5781000
CY2022Q4 seel Warrant Liabilities At Fair Value
WarrantLiabilitiesAtFairValue
132000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
15000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
58000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38928000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
25158000
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
8184000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
15000
CY2023Q4 us-gaap Liabilities
Liabilities
38928000
CY2022Q4 us-gaap Liabilities
Liabilities
33357000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
16000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
8000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9794594
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9794594
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3572417
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3572417
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
219106000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
204129000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252626000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214744000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-33510000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10611000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5418000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22746000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2203000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2203000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30117000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
58620000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12585000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12296000
CY2023 us-gaap Operating Expenses
OperatingExpenses
42702000
CY2022 us-gaap Operating Expenses
OperatingExpenses
70916000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-40499000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-70916000
CY2023 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
198000
CY2022 us-gaap Interest Income Domestic Deposits
InterestIncomeDomesticDeposits
121000
CY2023 us-gaap Interest Expense
InterestExpense
75000
CY2022 us-gaap Interest Expense
InterestExpense
14000
CY2023 seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-2049000
CY2022 seel Gain Loss In Fair Value Of Convertible Notes
GainLossInFairValueOfConvertibleNotes
-3017000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9151000
CY2023 seel Loss On Issuance Of Common Stock And Warrants
LossOnIssuanceOfCommonStockAndWarrants
-4301000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
17995000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
292000
CY2023 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2617000
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2618000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37882000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73534000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-7.73
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-20.74
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-7.73
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-20.74
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4900222
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3545691
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4900222
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3545691
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
57323000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5073000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8000
CY2022 seel Adjustments To Additional Paid In Capital Agreement To Repurchase Common Stock
AdjustmentsToAdditionalPaidInCapitalAgreementToRepurchaseCommonStock
-740000
CY2022 seel Issuance Of Common Stock For Prepaid Services
IssuanceOfCommonStockForPrepaidServices
167000
CY2022 seel Issuance Of Common Stock For License Acquired
IssuanceOfCommonStockForLicenseAcquired
841000
CY2022 seel Issuance Of Common Stock In At Market Offering Net Of Issuance Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfIssuanceCosts
152000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
99000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73534000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10611000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3988000
CY2023 seel Issuance Of Common Stock In At Market Offering Net Of Issuance Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfIssuanceCosts
68000
CY2023 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1010000
CY2023 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5139000
CY2023 seel Issuance Of Common Stock For Prepaid Services
IssuanceOfCommonStockForPrepaidServices
190000
CY2023 seel Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
-4481000
CY2023 seel Stock Issued During Period Of Common Stock Warrant Exercise Value
StockIssuedDuringPeriodOfCommonStockWarrantExerciseValue
10000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
97000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37882000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-33510000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-37882000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-73534000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3988000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5073000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-17995000
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-292000
CY2023 seel Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-2049000
CY2022 seel Change In Fair Value Of Convertible Notes Payable
ChangeInFairValueOfConvertibleNotesPayable
-3017000
CY2022 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1296000
CY2023 seel Loss On Issuance Of Common Stock And Warrants
LossOnIssuanceOfCommonStockAndWarrants
-4301000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
57000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
53000
CY2023 seel Net Loss On Extinguishment Of Convertible Debt
NetLossOnExtinguishmentOfConvertibleDebt
-9151000
CY2023 seel Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
763000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-5687000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2247000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
12777000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1933000
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4224000
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3522000
CY2022 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1174000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-58000
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-51000
CY2023 seel Increase Decrease In Licenses Payable
IncreaseDecreaseInLicensesPayable
-1000000
CY2022 seel Increase Decrease In Licenses Payable
IncreaseDecreaseInLicensesPayable
800000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23912000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61604000
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7641000
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1888000
CY2023 seel Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
20046000
CY2023 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
68000
CY2022 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
457000
CY2022 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
273000
CY2023 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1195000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
97000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
99000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11375000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1597000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12537000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-63201000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15533000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
78734000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2996000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15533000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
505000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2023 seel Fair Value Of Warrants Issued
FairValueOfWarrantsIssued
17415000
CY2023 seel Fair Value Of Warrants Issued In Extinguishment Of Convertible Notes
FairValueOfWarrantsIssuedInExtinguishmentOfConvertibleNotes
3247000
CY2023 seel Increase In Principal In Extinguishment Of Convertible Notes
IncreaseInPrincipalInExtinguishmentOfConvertibleNotes
4882000
CY2022 seel Stock Issued For License Payable
StockIssuedForLicensePayable
840000
CY2023 seel Deferred Offering Costs Accrued But Not Paid
DeferredOfferingCostsAccruedButNotPaid
541000
CY2022 seel Deferred Offering Costs Accrued But Not Paid
DeferredOfferingCostsAccruedButNotPaid
32000
CY2023 seel Issuance Of Common Stock For Cashless Exercise
IssuanceOfCommonStockForCashlessExercise
2000000
CY2023 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
1010000
CY2023 seel Issuance Of Common Stock For Interest Payments On Convertible Notes
IssuanceOfCommonStockForInterestPaymentsOnConvertibleNotes
4538000
CY2023 us-gaap Stock Issued1
StockIssued1
601000
CY2022 us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
86000
CY2022 seel Repurchase Of Common Stock Accrued But Not Paid
RepurchaseOfCommonStockAccruedButNotPaid
1195000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
480000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
16000000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of these consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of convertible notes payable, and the valuation of stock options. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</p>
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5868000
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
555000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q4 us-gaap Cash
Cash
3000000.0
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-252600000
CY2023Q4 seel Market Value For Common Stock Closes At Minimum Requirement
MarketValueForCommonStockClosesAtMinimumRequirement
35000000
CY2023Q4 seel Market Value For Common Stock Closes At Minimum Requirement
MarketValueForCommonStockClosesAtMinimumRequirement
35000000
CY2023Q4 seel Value Of Shares Available Under Registration Statement
ValueOfSharesAvailableUnderRegistrationStatement
250000000.0
CY2019Q1 seel Total Number Of Board Seats Of Combined Company
TotalNumberOfBoardSeatsOfCombinedCompany
5
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
51000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
104000
CY2023Q4 seel Prepaid Clinical Costs
PrepaidClinicalCosts
1516000
CY2022Q4 seel Prepaid Clinical Costs
PrepaidClinicalCosts
6837000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
77000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
200000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1644000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7141000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000000.0
CY2023 seel Non Refundable Cash Payments
NonRefundableCashPayments
1200000
CY2023 seel Research And Development Expenses Premium Paid
ResearchAndDevelopmentExpensesPremiumPaid
500000
CY2023Q4 seel Total Aggregate
TotalAggregate
239000000.0
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
250000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
278000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
56000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1288000
CY2023Q4 seel Outside Research And Development Services Current
OutsideResearchAndDevelopmentServicesCurrent
2152000
CY2022Q4 seel Outside Research And Development Services Current
OutsideResearchAndDevelopmentServicesCurrent
5627000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
58000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
89000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2516000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7282000
CY2022 seel Repayments Of Interest Of Convertible Notes
RepaymentsOfInterestOfConvertibleNotes
1900000
CY2023Q4 us-gaap Long Term Debt
LongTermDebt
14200000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
20000000.0
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
48784
CY2019Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
124.50
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
11274
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
20.76
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2434
CY2022 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
209
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
0
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
3988000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5073000
CY2023Q4 seel Tax Credit Carryforward Limitation On Taxable Income Rate
TaxCreditCarryforwardLimitationOnTaxableIncomeRate
0.80
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
33190000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27362000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
461000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
803000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1559000
CY2023Q4 seel Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Research And Expenses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndExpenses
14735000
CY2022Q4 seel Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Research And Expenses
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsResearchAndExpenses
11137000
CY2023Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
7256000
CY2022Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
8577000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
55986000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
49096000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55986000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
49096000
CY2023Q4 seel Deferred Tax Asset Gross Noncurrent
DeferredTaxAssetGrossNoncurrent
33200000
CY2022Q4 seel Deferred Tax Asset Gross Noncurrent
DeferredTaxAssetGrossNoncurrent
27400000
CY2022 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.010
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
0.014
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.044
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.129
CY2023 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.102
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.182
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.031
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
16000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
16000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
100000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-000140-index-headers.html Edgar Link pending
0001410578-24-000140-index.html Edgar Link pending
0001410578-24-000140.txt Edgar Link pending
0001410578-24-000140-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
seel-20231231.xsd Edgar Link pending
seel-20231231x10k.htm Edgar Link pending
seel-20231231xex23d1.htm Edgar Link pending
seel-20231231xex23d1001.jpg Edgar Link pending
seel-20231231xex31d1.htm Edgar Link pending
seel-20231231xex31d2.htm Edgar Link pending
seel-20231231xex32d1.htm Edgar Link pending
seel-20231231xex32d2.htm Edgar Link pending
seel-20231231xex4d6.htm Edgar Link pending
seel-20231231xex97.htm Edgar Link pending
Show.js Edgar Link pending
seel-20231231_cal.xml Edgar Link unprocessable
seel-20231231_def.xml Edgar Link unprocessable
seel-20231231_lab.xml Edgar Link unprocessable
seel-20231231_pre.xml Edgar Link unprocessable
seel-20231231x10k_htm.xml Edgar Link completed